首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial.
【24h】

Enhancing effect of HT008-1 on cognitive function and quality of life in cognitively declined healthy adults: a randomized, double-blind, placebo-controlled, trial.

机译:HT008-1对认知减退的健康成年人的认知功能和生活质量的增强作用:一项随机,双盲,安慰剂对照的试验。

获取原文
获取原文并翻译 | 示例
           

摘要

HT008-1 is one of the most effective multiherb mixtures that have neuroprotective effects in traditional Korean medicine. The purpose of this study was to conduct a clinical trial of the efficacy of HT008-1 on the neuropsychological functioning and quality of life (QoL) in cognitively intact adults. One hundred and eighteen male (n - 42) and female (n = 76) volunteers who reported no history of dementia or significant neurocognitive impairments and obtained Korean Version of Mini Mental State Examination total scores of at least 24 were examined via an 8-week, randomized, double-blind, fixed-dose, placebo-controlled, parallel group, clinical trial. Participants were randomly assigned to receive either HT008-1 (n = 59) or placebo (n = 59) for 8 weeks. Efficacy measures consisted of participants' performance scores from pretreatment baseline to those obtained just before termination of treatment on standardized neuropsychological measures from the subsets of Wechsler Memory Scale-III (WMS-III). QoL was assessed by subjective questionnaires WHOQoL-Bref about five categories. Participants who scored in the lower third of the Auditory recognition delayed at baseline and received HT008-1 exhibited improvement on the WMS-III Auditory recognition delayed subtest compared with placebo controls. The HT008-1 group also improved on general health scores in the QoL test.
机译:HT008-1是最有效的多草药混合物之一,在传统韩国医学中具有神经保护作用。这项研究的目的是进行HT008-1对认知完好成人的神经心理功能和生活质量(QoL)的疗效的临床试验。经过8周的检查,共有118名男性(n-42)和女性(n = 76)志愿者,他们没有痴呆史或严重的神经认知障碍史,并且获得了韩国迷你精神状态检查总成绩至少24分,随机,双盲,固定剂量,安慰剂对照,平行组,临床试验。参与者被随机分配接受HT008-1(n = 59)或安慰剂(n = 59)8周。功效测量包括参与者的治疗得分,这些得分是从治疗前的基线到即将终止治疗之前根据Wechsler Memory Scale-III(WMS-III)的子集进行的标准化神经心理学测量得出的。通过主观问卷WHOQoL-Bref评估有关五个类别的QoL。在听觉识别中得分较低的三分之一的参与者在基线时延迟并接受HT008-1,与安慰剂对照相比,WMS-III听觉识别延迟子测试表现出改善。 HT008-1组在QoL测试中的总体健康评分也有所提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号